Real-world Utilization of Mineralocorticoid Receptor Antagonists in India and the Benefits of GDMT in Heart Failure

Journal of the Association of Physicians of India 2026

View at publisher
Authors: Nilesh Gautam, Parijat D Chowdhury, Akash Batta, Rajeev K Gupta, Nishant Kannodia, K Krishna Prabhakar, Karthik Munichoodappa, Mihir Shah, Kaustubh Durve, Mohammed Nadeem, Vamsie Mohan, Febin Francis
+2 more Amarnath Sugumaran, Senthilnathan Mohanasundaram
DOI: 10.59556/japi.74.1297
Cited by: 0
References: 37

Abstract

Early initiation of guideline-directed medical therapies (GDMTs) in heart failure (HF) and their uptitration to the target dose confer mortality benefits and reduce the risk of readmission. GDMT nonuse is a significant predictor of mortality in HF patients. However, GDMT prescription and adherence in India are low. Of the GDMTs, mineralocorticoid receptor antagonists (MRAs) are the least prescribed. There are multilevel gaps [healthcare professional (HCP)-related, patient-related] in the adoption and use of MRAs in HF. There is an unmet need to identify these gaps and formulate mitigation strategies to close them. This can improve or enhance GDMT adoption in the HF treatment paradigm.

Fields of Study & Subjects

Heart Failure Treatment and Management Hormonal Regulation and Hypertension Atrial Fibrillation Management and Outcomes

Publication details

Journal / source
Journal of the Association of Physicians of India
Volume
74
Issue
1
Pages
27–31
Publication date
1 January 2026
Language
EN